Literature DB >> 28975572

Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?

E Poggiogalle1, L M Donini2, C Chiesa3, L Pacifico4, A Lenzi2, S Perna5, M Faliva5, M Naso6, M Rondanelli5.   

Abstract

PURPOSE: To investigate the association between fasting glucagon-like peptide 1 (GLP-1) levels and resting energy expenditure (REE), and respiratory quotient (RQ) in overweight and obese adults.
METHOD: Study participants were enrolled at the Dietetic and Metabolic Unit, University of Pavia, Italy. Inclusion criteria were age ≥ 25 and ≤ 45 years, and body mass index (BMI) ≥ 25 and ≤ 35 kg/m2. Diabetic subjects were excluded. Body composition was measured by dual-energy X-ray absorptiometry. REE was evaluated using indirect calorimetry, and RQ was calculated from respiratory gas exchanges. Fasting GLP-1, glucose, insulin and free fatty acid (FFA) levels, and 24-h norepinephrine urinary excretion were measured. Homeostasis model assessments of insulin resistance (HOMA-IR) and beta-cell function (HOMA-β) were calculated.
RESULTS: Thirty-seven participants were included (age 43.4 ± 1.6 years; BMI 30.6 ± 0.5 kg/m2). REE was not associated with fasting GLP-1 levels (p = 0.98) after adjustment for age, sex, fat-free mass (FFM), and fat mass (FM). Similarly, no association was observed between RQ and GLP-1 levels (p = 0.95), after adjustment for age, sex, and body fat.
CONCLUSION: In adults subjects with increased adiposity fasting, GLP-1 levels do not seem to play a role in the regulation of energy metabolism and in fuel selection.

Entities:  

Keywords:  Glucagon-like peptide 1; Norepinephrine; Obesity; Respiratory quotient; Resting energy expenditure

Mesh:

Substances:

Year:  2017        PMID: 28975572     DOI: 10.1007/s40618-017-0764-1

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

Review 1.  Best practice methods to apply to measurement of resting metabolic rate in adults: a systematic review.

Authors:  Charlene Compher; David Frankenfield; Nancy Keim; Lori Roth-Yousey
Journal:  J Am Diet Assoc       Date:  2006-06

2.  Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man.

Authors:  A Shalev; J J Holst; U Keller
Journal:  Eur J Clin Invest       Date:  1997-01       Impact factor: 4.686

Review 3.  Advances in our understanding of the role of the sympathetic nervous system in obesity.

Authors:  I A Macdonald
Journal:  Int J Obes Relat Metab Disord       Date:  1995-12

Review 4.  Fuel homeostasis and locomotor behavior: role of leptin and melanocortin pathways.

Authors:  G Ceccarini; M Maffei; P Vitti; F Santini
Journal:  J Endocrinol Invest       Date:  2014-12-13       Impact factor: 4.256

5.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

Authors:  Michael A Nauck; Markus M Heimesaat; Kai Behle; Jens J Holst; Markus S Nauck; Robert Ritzel; Michael Hüfner; Wolff H Schmiegel
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

6.  Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans.

Authors:  Nicola Pannacciulli; Joy C Bunt; Juraj Koska; Clifton Bogardus; Jonathan Krakoff
Journal:  Am J Clin Nutr       Date:  2006-09       Impact factor: 7.045

Review 7.  Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.

Authors:  Christopher A Lindamood; James R Taylor
Journal:  Clin Ther       Date:  2015-02-04       Impact factor: 3.393

8.  Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation.

Authors:  J J Hwa; L Ghibaudi; P Williams; M B Witten; R Tedesco; C D Strader
Journal:  Peptides       Date:  1998       Impact factor: 3.750

9.  Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.

Authors:  J van Can; B Sloth; C B Jensen; A Flint; E E Blaak; W H M Saris
Journal:  Int J Obes (Lond)       Date:  2013-09-03       Impact factor: 5.095

Review 10.  Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.

Authors:  Feng Sun; Sanbao Chai; Lishi Li; Kai Yu; Zhirong Yang; Shanshan Wu; Yuan Zhang; Linong Ji; Siyan Zhan
Journal:  J Diabetes Res       Date:  2015-01-20       Impact factor: 4.011

View more
  2 in total

1.  Fasting glucagon-like peptide 1 concentration is associated with lower carbohydrate intake and increases with overeating.

Authors:  A Basolo; S Heinitz; E J Stinson; B Begaye; M Hohenadel; P Piaggi; J Krakoff; S B Votruba
Journal:  J Endocrinol Invest       Date:  2018-10-03       Impact factor: 4.256

2.  Characteristics and resolution of hypertension in obese African American bariatric cohort.

Authors:  Charu Gandotra; Motahar Basam; Ankit Mahajan; Julius Ngwa; Gezzer Ortega; Daniel Tran; Terrence M Fullum; Zaki A Sherif
Journal:  Sci Rep       Date:  2021-01-18       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.